TLDRs;
- Ionis stock plunged 23% after Wainua failed to meet the primary endpoint in a pivotal Phase 3 heart disease trial.
- The setback erased roughly $3 billion in market value as investors reassessed Wainua’s long-term commercial opportunity.
- Analysts lowered price targets but largely maintained bullish ratings, citing strength across Ionis’ broader development pipeline.
- Investors are now shifting focus toward newly approved TRYNGOLZA and other commercial launches to drive future growth.
Ionis Pharmaceuticals (NASDAQ: IONS) suffered one of its steepest single-day declines of the year on Thursday after disappointing late-stage clinical trial results for Wainua dramatically altered investor expectations.
The biotechnology company’s shares plunged approximately 23% to around $64.83, erasing roughly $3 billion in market capitalization. The selloff stood out because it occurred despite broader biotechnology stocks posting gains, highlighting that the decline was driven by company-specific developments rather than weakness across the healthcare sector.
The negative reaction followed the announcement that Wainua, developed in partnership with AstraZeneca, failed to achieve the primary endpoint in the Phase 3 CARDIO-TTRansform study evaluating the treatment for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a progressive heart disease caused by abnormal transthyretin protein deposits.
Expansion Plans Face Setback
While Wainua is already approved for hereditary transthyretin-mediated amyloid polyneuropathy, the latest trial was designed to significantly expand its commercial potential into the much larger ATTR-CM market.
However, the study failed to demonstrate a statistically significant reduction in the combined risk of cardiovascular death and recurrent cardiovascular events over the 140-week trial period.
Ionis Pharmaceuticals, Inc., IONS
Researchers also found that patients already receiving transthyretin stabilizer therapies did not experience additional clinical benefit from adding Wainua to their treatment regimen.Although a subgroup of patients receiving Wainua as a standalone therapy appeared to perform better than placebo, those findings were considered exploratory and were not sufficient to offset the study’s overall failure.
The disappointing outcome significantly reduced expectations that Wainua could become a multibillion-dollar therapy in cardiomyopathy, prompting investors to rapidly reprice Ionis shares.
Analysts Remain Constructive
Despite the sharp market reaction, several Wall Street firms maintained positive ratings on Ionis while lowering their valuation estimates.Jefferies reduced its price target to $90 from $113 but reiterated its Buy recommendation, suggesting that unexpectedly strong performance from existing stabilizer therapies may have contributed to the trial outcome.
Similarly, TD Cowen lowered its target to $94 from $108 while maintaining a Buy rating, noting that Wainua’s monotherapy data remained broadly consistent with previous studies of competing transthyretin-lowering therapies.
Oppenheimer also reduced its valuation estimate while keeping an Outperform rating, arguing that although the failed study limits near-term upside, Ionis’ diversified pipeline continues to provide long-term growth opportunities.
Market participants had previously estimated that Wainua could eventually generate as much as $2 billion annually from the ATTR-CM indication, making the failed expansion study a meaningful blow to future revenue expectations.
Focus Shifts To Pipeline
Following the setback, investor attention is increasingly turning toward Ionis‘ independently commercialized products and broader pipeline.
Investors will now closely monitor the detailed Phase 3 data presentation at the European Society of Cardiology Congress in August, where researchers are expected to provide additional insight into the study results. Until then, the market is likely to focus on whether Ionis can offset the loss of Wainua’s expanded opportunity through successful commercialization of TRYNGOLZA and continued progress across its broader pipeline.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
